-- GCLテクノロジー（香港証券取引所：3800）の子会社であるGCLソーラースター・インベストメントは、1億4800万米ドルの社債発行を完了したと、同社が木曜日に香港証券取引所に提出した書類で発表した。 太陽光発電材料メーカーである同社の株価は、金曜日の午前中の取引終盤に2%以上下落した。 同社は、2027年満期、利率6.95%の保証付き転換社債を発行した。この社債は、当初転換株1株あたり1.21香港ドルでGCLテクノロジーの株式に転換可能である。 全株が転換された場合、この社債はGCLテクノロジーの株式9億5860万株に相当し、拡大ベースで同社の発行済み株式総数の2.80%を占めることになる。 この転換社債はウィーン証券取引所に上場された。 GCLテクノロジーは、社債発行による資金は、一般的な事業目的および債務返済に充当されると述べた。
Related Articles
Asia
Anhui Hwasu CFO Resigns
Anhui Hwasu (SHA:600935) said Bi Gang resigned as chief financial officer on Thursday due to a work transfer, according to a Friday filing with the Shanghai bourse.
$SHA:600935
Asia
Lotte Chemical Titan Incurs Wider Loss Despite 70% Higher Revenue
Lotte Chemical Titan (KLSE:LCTITAN) posted a wider first-quarter loss despite a 70% jump in revenue, according to a Thursday Malaysian bourse filing.Shares slid over 1% in Friday's midday trade.The loss widened as higher depreciation and financing costs from its Indonesia ethylene project weighed on earnings.Loss before tax rose to 230 million ringgit from 135 million ringgit a year earlier, even as revenue climbed to 2.53 billion ringgit from 1.49 billion ringgit.The higher revenue was driven by higher sales volumes from the Indonesia New Ethylene project that began commercial operations in October 2025.The group reported EBITDA of 150 million ringgit, compared with a negative EBITDA of 38 million ringgit a year earlier, while plant utilization improved to 61% from 46%.Lotte Chemical Titan said ongoing geopolitical tensions in the Middle East, particularly the Iran war, continue to create uncertainty in the global petrochemical market.
$KLSE:LCTITAN
Research
Research Alert: CFRA Maintains Strong Buy Opinion On Shares Of Axon Enterprise, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We decrease our 12-month target price by $92 to $693, or 65.0x our 2027 EPS estimate, a discount relative to AXON's average forward P/E of 92.7x (during the trailing-12-month period). We trim our EPS estimates for 2026 by $0.16 to $7.78 and 2027's by $0.12 to $10.66. AXON's fundamental strength remains compelling as the company extends its competitive moat through an integrated ecosystem that combines hardware, cloud software, and AI capabilities. With 30%+ revenue growth for nine consecutive quarters, AXON is capitalizing on a $159 billion TAM while penetrating less than 15% of its core U.S. market. Multiple growth drivers are accelerating simultaneously: AI Era Plan bookings surged 140% Y/Y with near-universal adoption among large agencies; Dedrone counter-drone revenue jumped 300% Y/Y; and international revenue doubled, reaching 20% of total sales. Axon's 125% net revenue retention and $14.3 billion in future contracted bookings (+44% Y/Y) underscore strong visibility.
$AXON